



BioReliance  
14920 Broschart Road  
Rockville, Maryland 20850-3349 USA  
Phone: 301.738.1000 • Fax: 301.738.1605  
www.bioreliance.com

## FOR IMMEDIATE RELEASE

Contacts:                    Scott Litherland  
                                  Parallax Communications Group  
                                  [slitherland@parallaxgroup.net](mailto:slitherland@parallaxgroup.net)  
                                  317/638-7898

                                  David Walker  
                                  Vice President & Chief Financial Officer  
                                  BioReliance Corporation  
                                  310/610-2866

### **BioReliance Names Darryl L. Goss to Lead New Toxicology/LADS Business Unit**

**Rockville, MD, April 8, 2008** -- BioReliance Corporation announced today Darryl L. Goss has been appointed Vice President, Toxicology/Laboratory Animal Diagnostic Services (LADS), a new executive position created to lead this newly formed Business Unit. Goss, who was previously Vice President, Global Process Excellence at BioReliance, will continue to serve on the company's Operating Committee and report to David A. Dodd, President, CEO and Chairman, BioReliance Corporation.

BioReliance Corporation is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries worldwide.

Mr. Goss will have direct responsibility for the operations and commercialization of the company's new Toxicology/LADS Business Unit, which combines the company's separate toxicology and LADS services. Other senior managers assigned to the Toxicology/LADS unit, reporting to Mr. Goss, include:

- David Bruning, appointed to Senior Director, Business Operations, responsible for sales, marketing, business development and program management activities;
- David McClelland, appointed to Director, Genetic Toxicology Operations, responsible for all laboratory operations in support of gene toxicology services;

- Eias Zahalka Ph.D., appointed to Director, Mammalian Toxicology Operations, responsible for all laboratory operations in support of mammalian toxicology services;
- Daniel Aparicio, appointed Director, LADS Operations, responsible for all laboratory operations in support of LADS.

“With his strong leadership skills and industry experience, Darryl is the ideal person to accelerate the growth of this critically important Business Unit,” said David A. Dodd, President, CEO and Board Chairman of BioReliance. “Our toxicology and LADS groups already rank among the world’s best, and are trusted by the world’s largest pharmaceutical and biopharmaceutical companies, discovery firms and government agencies, to deliver excellent testing performance. I am confident this new Business Unit, with its experienced staff and under Darryl’s leadership, will serve our existing and new clients at the highest level, accelerating our growth in this key area.”

“I look forward to the opportunity to work with the outstanding professionals in this business unit, who are among the finest in our industry,” said Mr. Goss. “We are committed to providing the very highest levels of testing services with on-time delivery to our valued clients. In addition, we are planning to strategically expand our services to meet the evolving needs of our clients.”

Mr. Goss has served as Vice President, Global Process Excellence since joining BioReliance in September 2007. Previously, he was Senior Vice President and COO of Esoterix, Inc., following its acquisition by LabCorp. From 2000 to 2005, he held a variety of executive positions at Esoterix including Senior Vice President of Business Operations and Chief Information Officer. From 1993 to 2000, he worked at Covance Central Laboratory Services, Inc., serving in several capacities including Vice President of Information Technology and Services. Prior to Covance, he held various information technology and business development positions with Smith Kline Beecham Clinical Laboratories, Guidance Opportunity, Inc., Beatrice Hunt-Wesson and IBM. Mr. Goss received a Master of Business Administration from University of Chicago, completed post-graduate work in Advanced Management at Oxford University in Oxford, England, and received his Bachelor of Arts degree from the University of California Davis.

In addition to the Toxicology/LADS Business Unit, BioReliance includes the existing Biologics Business Unit.

### **About BioReliance**

BioReliance Corporation is a leading specialist provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing, GMP manufacturing, pre-clinical testing and lab animal health diagnostics. Founded in 1947 as Microbiological Associates, BioReliance is headquartered in Rockville, Maryland, and has primary facilities in Rockville, Glasgow, Scotland, Stirling, Scotland, and Edinburgh, Scotland, employing more than 700 people globally. For more information, visit [www.bioreliance.com](http://www.bioreliance.com).

#####